Latest Breaking News On - Charanjit rihal - Page 2 : comparemela.com

April 19, 2021 Selecting a post-PCI antiplatelet regimen based on platelet function or genetic testing seems to improve both efficacy and safety, according to a new meta-analysis. Its authors say the results support the next frontier of personalized medicine despite the lack of randomized trial evidence. Prior studies, like last year’s TAILOR-PCI, have failed to establish the superiority of a guided antiplatelet strategy over standard therapy, but proponents say no trial so far has been accurately powered to do so. This 20,000-patient meta-analysis, which combined the TAILOR-PCI, POPular Genetics, TROPICAL-ACS, and PHARMCLO trials, among others, was designed to overcome prior research pitfalls, lead author Mattia Galli, MD (Catholic University of the Sacred Heart, Rome, Italy, and University of Florida College of Medicine, Jacksonville), told TCTMD.

Mattia galliDirk sibbingAdnan kastratiCharanjit rihalMd catholic university of the sacred heartUniversity of florida college medicineCatholic universitySacred heartFlorida collegeMayo clinicபல்கலைக்கழகம் ஆஃப் புளோரிடா கல்லூரி மருந்துகத்தோலிக் பல்கலைக்கழகம்புனிதமானது இதயம்புளோரிடா கல்லூரிமயோ சிகிச்சையகம்